BACKGROUND: To investigate the impact of predominantly upper body fat localisation on the hormonal and metabolic pro®le in obese, infertile women. DESIGN: Prospective observational study of premenopausal women with obesity, infertility and menstrual dysfunction. SETTING: Department of Endocrinology and Reproduction of the University Hospital of Obstetrics and Gynaecology of Heidelberg. SUBJECTS: Eighteen women with android type obesity (waist-hip-ratio WHR b 0.85, group 1) and 22 women with gynoid type obesity (WHR 0.85, group 2) in a group of 58 premenopausal obese women (median age 28 y) with infertility. Twenty-nine women took part in a weight reducing program lasting 32 AE 14 (mean AE s.d.) weeks. MEASUREMENTS: BMI, WHR and blood pressure. Plasma lipids and liver enzymes. Blood glucose, insulin, C-peptide and different steroid and pituitary hormones during oral glucose loading. RESULTS: In the total group of 58 obese women, WHR was directly correlated to plasma triglycerides, AST, ALT and cholesterol/HDL-cholesterol-ratio. WHR correlated inversely with HDL-cholesterol. Insulin resistance was greater with increasing WHR. Systolic blood pressure, glucose, insulin, C-peptide, triglycerides, cholesterol/HDL-cholesterol-ratio, aspartate (AST) and alanine aminotransferase (ALT) were signi®cantly greater in group 1. Group 2 had greater HDLcholesterol levels. One subject in group 1, ®ve women in group 2 conceived spontaneously after weight reduction. CONCLUSIONS: Determination of the WHR is a simple measurement to identify obese patients who are at a greater risk of developing the metabolic syndrome. WHR is important in preventive medicine, as typical metabolic pro®les are already present in young women before clinical manifestation. Women with android obesity seem to be more prone to develop menstrual irregularity and infertility. The hyperinsulinaemia may be the pathway.
Introduction
Obesity is a common health problem in western populations and associated with an increase in mortality and morbidity. 1±6 There is, for example, an increased prevalence of diabetes, cardiovascular disease, hyperlipidemia and certain tumours, for example rectal carcinoma. 1,4±11 At least 30% of the population of former West Germany is overweight. 2, 3 Body weight and body mass index (BMI) are commonly used to diagnose obesity in clinical practice. 1 The body fat distribution, simply measured by the waist to hip girth, is supposedly a more important factor in predicting the risk of related diseases than the grade of obesity as determined by the BMI. 1,3,6,12±17 Obesity is also considered a risk factor in the ®eld of obstetrics and gynaecology. 18±22 Obese women are more likely to suffer from infertility and menstrual dysfunction and respond less well to the usual hormonal treatment. 23±26 If pregnancy occurs, the rate of complications is higher during its course as well as during delivery. 27 There is also an increased prevalence of certain gynaecological tumours, for example endometrial or breast cancer, in obese women. 4, 8, 9, 28 We investigated two subgroups of premenopausal, obese women to evaluate whether the site of body fat predominance does predict a speci®c metabolic and hormonal pro®le already in young women. Furthermore, the effects of weight reduction on menstrual irregularity and infertility in these subgroups were evaluated. We previously found a pregnancy rate of 29% and an improvement of menstrual dysfunction in 80% in obese, infertile women after weight reduction. 29 
Materials and methods

Subjects
Fifty-eight obese, premenopausal women (BMI range 26.9±49.9 kg/m 2 ) with menstrual irregularity, aged 17±41 y, were selected for this study between November 1988 and February 1990. All women were referred to our department because of infertility of 6.5 AE 5.0 y (mean AE s.d.) duration. Inclusion criteria were: obesity, menstrual irregularity, normal thyroid function and normal prolactin levels (`20 ng/ml). Obesity was de®ned as body mass index (BMI) greater than 25 kg/m 2 .
3 BMI was calculated using the formula BMI body weight (kg)/height 2 (m 2 ). 1, 3 Abnormal length of menstrual cycles, chronic anovulation or luteal insuf®ciency (progesterone`10 ng/ml) was considered as menstrual irregularity. 30 Thirty-six ovarian ultrasounds proved multicystic ovaries in six subjects. Only one woman showed all criteria of the polycystic ovary syndrome (PCO-syndrome: hyperandrogenism, polycystic ovaries, abnormal LH-FSHratio b 2.0). 31 Body weight and height were determined in all 58 subjects. WHR was calculated by dividing the waist circumference at the narrowest place above the umbilicus by the hip circumference at the widest place. 1 As determinations of WHR were only started in February 1989, 40 women were measured: 18 women showed upper body segment obesity (android type, WHR b 0.85, group 1), 22 women lower body segment obesity (gynoid type, WHR 0.85, group 2). Systolic and diastolic blood pressure (Riva-Rocci) were measured in lying position: normal values: readings up to 140/90; borderline hypertension: 140±160/90±95; hypertensive readings: b 160/95. Eleven women with android and 18 women with gynoid obesity took part in a weight reduction program with reduced caloric intake of 20930± 41860 kJ per week (5000±10000 kcal per week).
Oral glucose tolerance test
After following a 250±300 g carbohydrate diet for 3 d, an oral glucose tolerance test (OGTT, 100 g, DextrooGT-glucose drink, Boehringer, Mannheim, Germany) was performed after an overnight fast at 0800 h during days 2±5 of the menstrual cycle. In patients with amenorrhoea, menstrual bleeding was induced by progestin challenge. Antecubital cannulation was performed 15 min prior to ®rst blood sampling. One fasting and four venous blood samples after glucose loading were taken at hourly intervals (0, 60, 120, 180 and 240 min). Insulin, connecting peptide (C-peptide), oestradiol, testosterone, dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulphate (DHEAS), androstene dione, cortisol, adrenocorticotrophic hormone (ACTH) and growth hormone (GH) were assayed in each sample. Single measurements (0 min) of prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and a biochemical pro®le including triglycerides, cholesterol, high density lipoprotein (HDL)-cholesterol, AST, ALT and gGT were performed. Hourly capillary blood sugar (Glucostix, Bayer, Leverkusen, Germany) was measured photometrically with a re¯ectometer (Ames). Normal values were:`100 mg/dl at 0, 180, 240 min; 160 mg/dl at 60 min;`120 mg/dl at 120 min. Pathological values were: b 130 mg/dl at 0, 180, 240 min; b 220 mg/dl at 60 min; b 150 mg/dl at 120 min. All values between these areas were considered as borderline. Glucose tolerance was normal with all values in the normal range or the peak value in the borderline area. It was considered as pathological with all values in the pathological range and the fasting value in the borderline or pathological area. Any other possibility was regarded as impaired glucose tolerance. Insulin resistance was calculated by dividing fasting blood sugar by fasting insulin. 1 Values less than six were considered as pathological. Hyperinsulinaemia was de®ned as fasting insulin levels greater than 24 mU/ml.
Biochemical determinations
LH, FSH and prolactin were assayed using immunouorescence kits (LKB-Pharmazia, Helsinki, Finland). The following hormone determinations were performed by radioimmunoassay (RIA): 17b-oestradiol (TRAVENOL, Dudingen, Switzerland), GH (SERONO Diagnostika GmBH, Freiburg, Germany), insulin and C-peptide (Diagnostic Products Corporation, Bad Nauheim, Germany) and ACTH (ACTHAllegro kit, Nichols-Institute, Bad Neuheim, Germany). Testosterone and DHT were extracted with help of dichlormethan and chromatography in a benzol-heptan-methanol-water-system (300:500/ 560:240). Separation was performed with testosterone-antibodies and radioactive, tritium-labelled 5-DHT. DHEAS was assayed after 1:600 solution with direct RIA. DHEA was determined with DHEA-antibodies after extraction with dichlormethan and chromatography in a benzol-heptan-methanl-water-system (250:150/220:120). Androstenedione determination was performed after extraction with isooctane. Cortisol was measured after extraction with ethanol. Determinations of AST, ALT, gGT, triglycerides, cholesterol and HDL-cholesterol were performed in the routine laboratory of the Medical University Hospital of Heidelberg (Ludolf-Krehl-Klinik, Prof. Dr. Fiehn) with standardized methods. Cholesterol/ HDL-cholesterol-ratio was calculated by dividing cholesterol by HDL-cholesterol. Ratios greater than four are associated with an increased cardiovascular risk. 32 The intraassay coef®cient of variation was less than 10% for all methods applied. The interassay coef®cient of variation was as follows: 11.1% for LH, 10.8% for FSH, 10.4% for prolactin, 15.6% for testosterone and DHT and 12±15% for ACTH, cortisol, androstenedione, DHEA and DHEAS. It was less than 10% for all other methods applied.
Statistical analysis
Statistical analysis was performed using the Statistical Analysis Program Package (SAS Institute, 1985) . Non-parametric methods were applied as the variables were not normally distributed. Comparisons between groups were made using the Mann-Whitney-Wilcoxon U-test. Values are expressed as median (25th±75th percentile) unless otherwise stated. w 2 test and Fisher's exact test were used for ordinal variables, the Spearman correlation coef®cient for correlation analysis. 33 Differences were considered signi®cant at P`0.05.
Results
Women with android obesity had signi®cantly greater systolic blood pressure readings ( Table 1 ). The hormonal differences between groups are shown in Fig  ures 1 and 2 . Blood sugar, insulin and C-peptide levels were signi®cantly higher in women with android obesity versus group 2. Women with android obesity were hyperinsulinaemic in 72%, subjects with gynoid obesity in 38% (P`0.05). No signi®cant differences were found in the percentage of impaired or pathological glucose tolerance between groups (group 1: 61% impaired, 6% pathological versus group 2: 45% impaired). Despite a tendency to higher ACTH and lower DHEA and cortisol concentrations in women with android obesity, the level of signi®cance was only reached at one time point following oral glucose load for each hormone. No signi®cant differences were found in LH, FSH, GH, androstenedione, testosterone, DHT, DHEAS, and oestradiol concentrations . jj QD gynoid: quartile difference 75th±25th percentile in the group of women with gynoid obesity. ±r± median android: median in the group of women with android obesity (group 1). ±j± Median gynoid: median in the group of women with gynoid obesity (group 2). P signi®cance. Figure 2 Insulin and C-peptide in the group of women with android obesity and the group of women with gynoid obesity. Time 0 fasting values, 60±240 min after oral glucose load. u QD android: quartile difference 75th±25th percentile in the group of women with android obesity (group 1). jj QD gynoid: quartile difference 75th±25th percentile in the group of women with gynoid obesity. ±r± median android: median in the group of women with android obesity (group 1). ±j± Median gynoid: median in the group of women with gynoid obesity (group 2). P signi®cance.
WHR and BMI in young obese women M Hollmann et al 479 between groups. In the total group of 58 obese women, WHR correlated inversely with the ratio of fasting glucose to insulin (Spearman correlation coef®cient r 70.35, P`0.05). Thus, the more insulin resistance a subject was, the higher was the WHR.
AST, gGT, tryglycerides, and the cholesterol/HDLcholesterol-ratio were signi®cantly higher in women with android obesity (Table 2) . Hypertriglyceridaemia was found in 53% of group 1-patients and 9% of group 2-patients (P`0.01). Cardioprotective HDLcholesterol was signi®cantly greater in group 2. All patients in group 1 vs 57% in group 2 had a cholesterol/HDL-cholesterol-ratio greater than four (P`0.01).
In the total group of 58 obese women, WHR correlated directly with triglycerides, cholesterol/ HDL-cholesterol-ratio, AST, gGT, and inversely with HDL-cholesterol ( Table 3 ). Triglycerides and ALT were associated closer with the BMI and % excess weight than with the WHR. Whereas no correlation was found between the BMI or excess weight and HDL-cholesterol or cholesterol/HDLcholesterol-ratio.
The achieved weight loss in group 1 was 7.5 (4±11) kg vs 10 (6.1±18.7) kg in group 2 after 32 AE 14 weeks (mean AE s.d.) (n.s.). One patient in group 1 vs 5 patients in group 2 conceived spontaneously after weight reduction without additional therapy (n.s.). On dividing the group of 58 obese women according to the BMI, 7 women had grade 1-(BMI 25.0±29.9 kg/m The difference was also signi®cant at 120 min after glucose load with 149 (138±173) mg/dl compared with to the groups with grade 2-obesity (110, 96± 133 mg/dl) or grade 1-obesity (85, 73±108 mg/dl; P`0.05). Serum testosterone levels at 120 min (41, 22±61 mg/dl) and 180 min (40, 19 .6±54 mg/dl) were signi®cantly higher in the group with grade 2-obesity compared to grade 1 subjects (21, 14±25 mg/dl and 19.3, 1743 mg/dl respectively; P`0.05). However, no signi®cant difference was found compared to grade 3 subjects. BMI correlated directly with triglycerides and liver enzymes (Table 3) .
Discussion
When analyzing the results of our study, one has to consider that we investigated a highly selected population of obese, infertile women, Nevertheless, in this group of young obese women with a mean age of 28.8 AE 5 y, android obesity was associated with signi®cantly higher levels of systolic blood pressure, blood glucose, AST and gGT. The risk of cardiovascular disease was increased as indicated by a signi®cantly greater percentage of patients with hypertriglyceridaemia, higher cholesterol/HDLcholesterol-ratios and suppressed HDL-cholesterol. In agreement with our results, the associations between android obesity and the metabolic syndrome has been shown in previous studies. 1, 3, 5, 6, 13, 17 Assessing the WHR is a simple procedure to identify obese risk patients. 1, 3 Interestingly, the differences in the metabolic pro®le, which depend on the body fat distribution, can already be found in young patients Table 3 Correlations (Spearman coef®cient) between serum lipids or liver enzymes and the body weight (kg), body mass index (BMI, kg/m 2 ), excess body weight (%) and the waist-hip-ratio (WHR) in the total group of 58 obese, infertile women Signi®cance: * P`0.05; ** P`0.01; *** P`0.001. prior to clinical manifestation of obesity-related disorders. Thus, measuring the WHR facilitates preventive medicine through identi®cation and rigorous treatment of these risk patients. On dividing the group of obese women according to the BMI, we could not associate speci®c metabolic pro®les with different grades of obesity. As previously demonstrated, the WHR is of greater importance than the BMI in predicting the risk of metabolic complications. 1, 3, 6, 16 Obesity, especially android type obesity, is commonly associated with the insulin resistant state and secondary hyperinsulinaemia. 1, 3, 6, 12, 18, 20, 34, 35 We also found signi®cantly higher insulin levels in women with android obesity. The insulin resistance was greater with increasing WHR. The insulin resistance is discussed as the common pathway leading to the metabolic complications in obesity. 1, 10, 12, 20, 36, 37 Insulin has been found to cause arteriosclerotic lesions and a proliferation of vascular smooth muscle cells and to promote renal tubular sodium and water absorption which may contribute to the development of cardiovascular disease. 1, 10, 37, 38 Insulin resistance results in an increased hepatic glucose release, and a decreased catabolism of triglycerides contributing to an impaired glucose tolerance and to reduced HDL-cholesterol levels. 1, 10 The metabolic complications of android obesity may be mediated by the more pronounced hyperinsulinaemia. However, we did not ®nd any correlations between insulin levels and metabolic parameters.
In the ®eld of gynaecology, obesity is associated with menstrual irregularity, chronic anovulation, and the PCO-syndrome. 23 ,24,34±36,39±41 Especially women with android obesity seem to be prone to develop menstrual disorders. 12, 15, 18, 20, 22, 34 Even in lean women, an increasing WHR was associated with a reduced chance of conception. 24 The possible role of insulin as the mediating factor has aroused a great deal of interest in recent years. Receptors for insulin have been demonstrated in human ovaries. 12, 42 In vivo and in vitro studies showed a direct stimulatory effect of insulin on ovarian androgen secretion acting in synergism with LH. 12, 19, 42, 43 In those obese women susceptible to the development of menstrual irregularity, an additional, genetically determined defect of androgen-secreting tissues, resulting in a greater insulin sensitivity than in normal ovaries, was postulated. 12, 20 The increased androgen concentrations serve as substrates for active aromatization into oestrogens in the body fat compartment which is an important source of oestrogens in obese women. 9, 12, 20 The resulting hyperoestrogenaemia is thought to modulate pituitary gonadotrophin release by increasing LH and decreasing FSH secretion. 12, 15, 23, 34, 39 Increased LH levels result in further stimulation of the androgen production. Ovarian follicular maturation deteriorates due to the lack of FSH and the increased androgen concentrations in the ovary. After a variable period of time, these hormonal changes lead to the polycystic morphology of the ovaries due to chronic anovulation. 12, 20, 39 Some studies observed a high prevalence of hyperandrogenaemia in women with android obesity. 5, 12, 13, 44 By contrast, this could not be con®rmed by other authors in agreement with our results. 13, 45 However, they found increased free androgen and decreased SHBG levels, thus increased free androgenic activity in subjects with android obesity. 13, 14, 16, 18, 45 Other studies noted an inverse association between insulin and SHBG. Insulin itself could cause increased androgenic activity by decreasing SHBG levels. 13, 14, 20, 34, 46, 47 Despite increased insulin levels in women with android obesity, we could not ®nd any differences in androgens, oestrogens or gonadotrophins in comparison to women with gynoid obesity. We did not observe any correlation between WHR, insulin or androgens. Both groups of obese women complained of infertility, however, which may imply hormonal differences in comparison to women with simple obesity. The prevalence of 45% of women with android obesity in a group of women with menstrual irregularity exceeded the normally observed rate of 10±20%. 5 Women with upper body segment obesity seem to be more prone to develop menstrual dysfunction. We could not identify a certain mechanism, for example the hyperinsulinaemia, to be responsible for this observation. However, the hyperinsulinaemia may act through mechanisms we did not investigate in our study, for example free hormone concentrations, SHBG levels or insulin-like growth factors.
Weight loss and physical activity are recommended as therapy of both types of obesity. 1, 29, 36, 48 We previously found a pregnancy rate of 29% and an improvement of menstrual dysfunction in 80% in obese, infertile women after simple weight reduction. 29 Further controlled studies are necessary to investigate whether weight loss, pregnancy rate and changes of menstrual dysfunction generally differ depending on the body fat distribution.
Conclusions
In summary, the WHR is a valuable parameter in identifying those obese patients who are at a greater risk of developing obesity-related disorders. As we found higher levels of systolic blood pressure, triglcyerides, blood sugar, liver enzymes and lower cardioprotective HDL-cholesterol concentrations already in a group of young women with android obesity compared to subjects with lower body fat localisation, the WHR could play a role in preventive medicine. One can identify risk patients prior to manifestation of diseases and treat them more rigorously. Women with upper body segment obesity seem to be more prone to develop menstrual disorders. The more pronounced hyperinsulinaemia in women with upper body fat localisation may be the link to the abnormal ovarian function.
